CoChat

Antifungal Drugs: The Current Armamentarium and Development of New Agents

Robbins, Nicole, Wright, Gerard D., Cowen, Leah E. · 2016 · Microbiology Spectrum

The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.

Abstract

Invasive fungal infections are becoming an increasingly important cause of human mortality and morbidity, particularly for immunocompromised populations. The fungal pathogens Candida albicans , Cryptococcus neoformans , and Aspergillus fumigatus collectively contribute to over 1 million human deaths annually. Hence, the importance of safe and effective antifungal therapeutics for the practice of modern medicine has never been greater. Given that fungi are eukaryotes like their human host, the number of unique molecular targets that can be exploited for drug development remains limited. Only three classes of molecules are currently approved for the treatment of invasive mycoses. The efficacy of these agents is compromised by host toxicity, fungistatic activity, or the emergence of drug resistance in pathogen populations. Here we describe our current arsenal of antifungals and highlight current strategies that are being employed to improve the therapeutic safety and efficacy of these drugs. We discuss state-of-the-art approaches to discover novel chemical matter with antifungal activity and highlight some of the most promising new targets for antifungal drug development. We feature the benefits of combination therapy as a strategy to expand our current repertoire of antifungals and discuss the antifungal combinations that have shown the greatest potential for clinical development. Despite the paucity of new classes of antifungals that have come to market in recent years, it is clear that by leveraging innovative approaches to drug discovery and cultivating collaborations between academia and industry, there is great potential to bolster the antifungal armamentarium.

Overview

Integrity signals

Registry

Crossref · 10.1128/microbiolspec.funk-0002-2016

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 183 references

Research works printed but not linked: 1

  1. CDC. 2013. Antibiotic Resistance Threats in the United States 2013 . CDC Atlanta GA. [PubMed]

Cited by

Items 301–319 of 319

Metadata

Authors
Robbins, N., Wright, G. D., & Cowen, L. E.
Affiliations
  • Michael G. DeGroote Institute for Infectious Disease Research (CA)
  • University of Toronto (CA)
Venue
Microbiology Spectrum
Published
2016-10-14
Volume
4
Issue
5
ISSN
2165-0497 (ISSN-L)
OpenAlex
W2532305189
Cited by
271
References
182
Citations by year
2026: 24 · 2025: 46 · 2024: 46 · 2023: 45 · 2022: 22 · 2021: 29 · 2020: 27 · 2019: 17 · 2018: 10 · 2017: 5
FWCI
9.84
Type
journal article
Language
en
Open access
closed
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Microbiology Spectrum (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords
antifungal agents, invasive fungal infections, antifungal resistance, Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, antifungal drug development, antifungal drug targets, combination antifungal therapy, drug toxicity, immunocompromised patients, novel antifungal agents
MeSH terms
Animals, Antifungal Agents, Fungi, Humans, Mycoses

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.